CorWave Announces Promising Results from First-In-Human Implant at HFSA Meeting

CorWave has announced the presentation of late-breaking results from its first-in-human implant study of its Left Ventricular Assisting System (LVAS) at the Heart Failure Society of America annual meeting. The results showed that the device was safe and effective, with no device-related adverse events observed at 30 days. The patient's functional status improved to NYHA class I before discharge and underwent a successful heart transplant on post-operative day 84. The CorWave LVAS preserved aortic pulse pressure and allowed consistent aortic valve opening despite a post-operative LVEF of 15%-20%. The study suggests that CorWave LVAS has the potential to offer significant benefits for patients with heart failure.

CorWave Inc. has announced the presentation of late-breaking results from its first-in-human implant study of its Left Ventricular Assisting System (LVAS) at the Heart Failure Society of America annual meeting. The study, conducted to evaluate the safety and efficacy of the CorWave LVAS, demonstrated promising outcomes for patients with heart failure.

The LVAS was found to be safe and effective, with no device-related adverse events observed at 30 days post-implantation. The device significantly improved the functional status of patients, with one patient's functional status improving to NYHA class I before discharge. Additionally, the patient underwent a successful heart transplant on post-operative day 84, highlighting the potential of the device to bridge patients to transplant.

The CorWave LVAS preserved aortic pulse pressure and allowed consistent aortic valve opening despite a post-operative left ventricular ejection fraction (LVEF) of 15%-20%. These findings suggest that the LVAS has the potential to offer significant benefits for patients with heart failure, including improved quality of life and extended survival.

The study results were presented by CorWave at the Heart Failure Society of America annual meeting, which took place from September 10 to 12, 2025. The meeting provided a platform for CorWave to share its latest innovations and advancements in heart failure treatment with a wide range of stakeholders, including healthcare professionals, researchers, and industry experts.

CorWave has been at the forefront of developing innovative solutions for heart failure patients, and the LVAS represents a significant step forward in the field. The company's commitment to advancing medical technology and improving patient outcomes is evident in the promising results of this study. As the company continues to refine and optimize its LVAS, it remains poised to make a meaningful impact on the treatment of heart failure.

References
BioCardia Reveals Plans to Request Meeting With FDA Regarding CardiAMP Heart Failure Cell Therapy^[1] https://www.cgtlive.com/view/biocardia-reveals-plans-request-meeting-fda-regarding-cardiamp-heart-failure-cell-therapy
Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera^[2] https://www.businesswire.com/news/home/20250303474433/en/Protagonist-and-Takeda-Announce-Positive-Topline-Results-from-Phase-3-VERIFY-Study-of-Rusfertide-in-Patients-with-Polycythemia-Vera